Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19

Clin Microbiol Infect. 2023 May;29(5):660-662. doi: 10.1016/j.cmi.2023.01.016. Epub 2023 Jan 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19*
  • Humans
  • Ritonavir / therapeutic use

Substances

  • nirmatrelvir
  • Ritonavir
  • Antiviral Agents